This systematic review and meta-analysis aims to synthesize evidence from randomized controlled trials (RCTs) to evaluate the efficacy of SGLT2 inhibitors in reducing hospitalization for heart failure among patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.